Status:

COMPLETED

Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction

Lead Sponsor:

Radboud University Medical Center

Collaborating Sponsors:

Dutch Diabetes Research Foundation

Conditions:

Type 2 Diabetes Mellitus Related Endothelial Dysfunction

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine whether atazanavir use is of influence on the endothelial dysfunction associated with type 2 diabetes mellitus.

Eligibility Criteria

Inclusion

  • Inclusion Criteria (most important):
  • 18 - 70 years
  • type 2 diabetes mellitus treated with diet, oral medication and/or insulin
  • BMI of 18 to 35
  • determinants of renal and hepatic function within twice the upper limit of normal range, abnormalities in lipid profile permitted
  • Exclusion Criteria (most important):
  • history of smoking within past year
  • history of or current abuse of drugs, alcohol or solvents
  • current use of antihypertensive, cardiac or other vasoactive medication
  • clinical evidence of cardiac or pulmonary disease

Exclusion

    Key Trial Info

    Start Date :

    June 1 2008

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 1 2009

    Estimated Enrollment :

    16 Patients enrolled

    Trial Details

    Trial ID

    NCT00696722

    Start Date

    June 1 2008

    End Date

    March 1 2009

    Last Update

    January 26 2010

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Radboud University Nijmegen Medical Centre

    Nijmegen, Gelderland, Netherlands, 6500